Early Treatment Considerations for IPF

Fernando J. Martinez, MD, MS; Kevin R. Flaherty, MD, MS


May 27, 2020

When should treatment be initiated for patients in the early stages of idiopathic pulmonary fibrosis (IPF)? Early treatment with one of two FDA-approved medications that can slow the permanent decline of lung function is often recommended, but the decision may be made more difficult when factoring in comorbidities, lifestyle preferences, and drug side-effect profiles.

In this panel ReCAP, Dr Fernando Martinez of Weill Cornell and Dr Kevin Flaherty of the University of Michigan discuss their approaches to decisions regarding early treatment of IPF. They compare side-effect profiles of IPF medications, consider the risk for acute exacerbations in patients with early disease, and discuss recent registry data on the decline in lung function in different patient populations.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.